Abstract
We aimed to compare safety and effectiveness of new class III antiarrhythmic drug Refralon with direct current cardioversion (DCC) in patients with persistent atrial fibrillation (AFib). 60 patients with persistent AFib were randomized to groups of DCC (n=30) and pharmacological conversion (PCV; n=
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
